Lu Khng s dng cho ngi mn cm, king k vi bt k thnh phn no ca sn phm
FDA Approves Oral Semaglutide as the First Oral GLP-1 Pill
GLP-1 receptor agonists should be considered in patients with type II diabetes and high ASCVD risk OR patients without diabetes who are overweight/obese and have a history of cardiovascular disease
The hormonal changes from weight loss can affect menstrual cycles, PCOS symptoms, and thyroid function simultaneously, creating a complex picture that requires experienced medical oversight
Moreover, the association observed in some epidemiological studies could be sustained by the fact that T2DM and TC could share some common risk factors, such as obesity and increasing age (Kitahara et al., 2020), and TC is often diagnosed incidentally in patients with T2DM due to the performance of screening imaging (such as carotid artery ultrasound), potentially leading to a selection bias ( The second reason why anti-diabetic drugs could be beneficial in TC is that TC cells often display abnormal metabolic pathways that could be sensitive to the specific action of anti-diabetic drugs